FDA "Drug Watch" Listing Removal Criteria Need Greater Clarity - PhRMA
Executive Summary
FDA's criteria for removing a product from the proposed "Drug Watch" website are subjective and will make it difficult, if not impossible, for a drug to be taken off the list, the Pharmaceutical Research & Manufacturers of America said
You may also be interested in...
FDA To Continue Providing Emerging Safety Info, But Not Through Drug Watch
Despite FDA's decision to drop its proposed "Drug Watch" Web site, the agency will continue to make emerging drug safety information available to the public
FDA To Continue Providing Emerging Safety Info, But Not Through Drug Watch
Despite FDA's decision to drop its proposed "Drug Watch" Web site, the agency will continue to make emerging drug safety information available to the public
FDA Stays Positive On Rx Safety Info Sheets, But Drug Watch Still In Question
Drug information sheets published by FDA in 2005 demonstrate the agency's focus on important safety issues, Drug Safety Oversight Board Executive Director Susan Cummins said Jan. 23 at a Drug Information Association conference in Washington, D.C